{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:14:50Z","timestamp":1790115290727,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Familial hypercholesterolemia (FH) is an inherited metabolic defect leading to increased total cholesterol and low-density cholesterol (LDL) from birth onwards. Homozygous FH, presenting with clear clinical features, has a prevalence of\u2009~\u20091 per million. Prevalence of heterozygous FH is 1\/500 European population. Atherosclerotic burden depends on the degree and duration of high LDL exposure. In severe cases, early detection is critical, and aggressive lipid-lowering therapies should begin in early childhood to reduce coronary heart disease risk. Pediatric therapeutic concepts correspond to adults and are orientated at LDL plasma concentration. Mean LDL plasma target value during treatment is\u2009&lt;\u2009135\u00a0mg\/dL. Medication in childhood consists of ezetemibe, statins, resins, and PCSK-9 inhibitors, with consideration for age restrictions. Only a minority achieve the treatment target with drug therapy alone. Therapeutic apheresis for the treatment of hypercholesterolemia selectively removes lipoproteins from blood (lipid apheresis (LA)). LA has a long tradition in adult medicine and is also safely used in children by a variety of methods, if customized to special pediatric needs. LA reduces cholesterol levels independently of residual LDL-receptor function and not only achieves reduction or disappearance of xanthomas but also inhibits progression of or mitigates aortic valve stenosis and supravalvular aortic stenosis as well as coronary artery and other atherosclerotic lesions. Cardiovascular prognosis of patients with otherwise untreatable FH depends largely on timely use of LA. Taking into account LA as a lifelong treatment, starting early in childhood, it is important to accommodate therapy modalities, such as treatment frequency and point of time, into the life of the individual.<\/jats:p>","DOI":"10.1007\/s00467-022-05541-1","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T10:03:56Z","timestamp":1650881036000},"page":"371-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["An update on lipid apheresis for familial hypercholesterolemia"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9585-054X","authenticated-orcid":false,"given":"Christina","family":"Taylan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"5541_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3181\/00379727-80-19629","volume":"80","author":"WS Adams","year":"1952","unstructured":"Adams WS, Blahd WH, Bassett SH (1952) A method of human plasmapheresis. Proc Soc Exp Biol Med 80:377\u2013379. https:\/\/doi.org\/10.3181\/00379727-80-19629","journal-title":"Proc Soc Exp Biol Med"},{"key":"5541_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/s0140-6736(76)93089-0","volume":"1","author":"CM Lockwood","year":"1976","unstructured":"Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB (1976) Immunosuppression and plasma-exchange in the treatment of Goodpasture\u2019s syndrome. Lancet 1:711\u2013715. https:\/\/doi.org\/10.1016\/s0140-6736(76)93089-0","journal-title":"Lancet"},{"key":"5541_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1046\/j.1537-2995.1999.39399219285.x","volume":"39","author":"BC McLeod","year":"1999","unstructured":"McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ et al (1999) Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 39:282\u2013288. https:\/\/doi.org\/10.1046\/j.1537-2995.1999.39399219285.x","journal-title":"Transfusion"},{"key":"5541_CR4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1172\/JCI107332","volume":"52","author":"JL Goldstein","year":"1973","unstructured":"Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG (1973) Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544\u20131568. https:\/\/doi.org\/10.1172\/JCI107332","journal-title":"J Clin Invest"},{"key":"5541_CR5","unstructured":"Scriver CR (2001) The metabolic & molecular bases of inherited disease. Volume II Volume II. New York: McGraw-Hill"},{"key":"5541_CR6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1172\/JCI114531","volume":"85","author":"E Leitersdorf","year":"1990","unstructured":"Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH (1990) Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 85:1014\u20131023. https:\/\/doi.org\/10.1172\/JCI114531","journal-title":"J Clin Invest"},{"key":"5541_CR7","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG (2020) Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 75:2553\u20132566. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.057","journal-title":"J Am Coll Cardiol"},{"key":"5541_CR8","unstructured":"Database LOV: http:\/\/www.ucl.ac.uk\/fh\/. (2022). Accessed."},{"key":"5541_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/tacg.s8285","volume":"3","author":"I De Castro-Oros","year":"2010","unstructured":"De Castro-Oros I, Pocovi M, Civeira F (2010) The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. Appl Clin Genet 3:53\u201364. https:\/\/doi.org\/10.2147\/tacg.s8285","journal-title":"Appl Clin Genet"},{"key":"5541_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/aje\/kwh236","volume":"160","author":"MA Austin","year":"2004","unstructured":"Austin MA, Hutter CM, Zimmern RL, Humphries SE (2004) Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 160:407\u2013420. https:\/\/doi.org\/10.1093\/aje\/kwh236","journal-title":"Am J Epidemiol"},{"key":"5541_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5551\/jat.CR003","volume":"25","author":"M Harada-Shiba","year":"2018","unstructured":"Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M et al (2018) Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb 25:751\u2013770. https:\/\/doi.org\/10.5551\/jat.CR003","journal-title":"J Atheroscler Thromb"},{"key":"5541_CR12","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1210\/jc.2002-021487","volume":"88","author":"M Harada-Shiba","year":"2003","unstructured":"Harada-Shiba M, Takagi A, Miyamoto Y, Tsushima M, Ikeda Y, Yokoyama S et al (2003) Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 88:2541\u20132547. https:\/\/doi.org\/10.1210\/jc.2002-021487","journal-title":"J Clin Endocrinol Metab"},{"key":"5541_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","volume":"223","author":"FJ Raal","year":"2012","unstructured":"Raal FJ, Santos RD (2012) Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223:262\u2013268. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.02.019","journal-title":"Atherosclerosis"},{"key":"5541_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","volume":"233","author":"J Besseling","year":"2014","unstructured":"Besseling J, Kindt I, Hof M, Kastelein JJ, Hutten BA, Hovingh GK (2014) Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 233:219\u2013223. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.12.020","journal-title":"Atherosclerosis"},{"key":"5541_CR15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","volume":"102","author":"DM Kolansky","year":"2008","unstructured":"Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE et al (2008) Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 102:1438\u20131443. https:\/\/doi.org\/10.1016\/j.amjcard.2008.07.035","journal-title":"Am J Cardiol"},{"key":"5541_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/hrt.80.6.583","volume":"80","author":"L Rallidis","year":"1998","unstructured":"Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P (1998) Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 80:583\u2013590. https:\/\/doi.org\/10.1136\/hrt.80.6.583","journal-title":"Heart"},{"key":"5541_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","volume":"363","author":"A Wiegman","year":"2004","unstructured":"Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD et al (2004) Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 363:369\u2013370. https:\/\/doi.org\/10.1016\/S0140-6736(04)15467-6","journal-title":"Lancet"},{"key":"5541_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.amjcard.2020.09.015","volume":"136","author":"C Taylan","year":"2020","unstructured":"Taylan C, Driemeyer J, Schmitt CP, Pape L, Buscher R, Galiano M et al (2020) Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis. Am J Cardiol 136:38\u201348. https:\/\/doi.org\/10.1016\/j.amjcard.2020.09.015","journal-title":"Am J Cardiol"},{"key":"5541_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CRD.0000000000000014","volume":"22","author":"M Weinreich","year":"2014","unstructured":"Weinreich M, Frishman WH (2014) Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev 22:140\u2013146. https:\/\/doi.org\/10.1097\/CRD.0000000000000014","journal-title":"Cardiol Rev"},{"key":"5541_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","volume":"58","author":"L Joseph","year":"2015","unstructured":"Joseph L, Robinson JG (2015) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis 58:19\u201331. https:\/\/doi.org\/10.1016\/j.pcad.2015.04.004","journal-title":"Prog Cardiovasc Dis"},{"key":"5541_CR21","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJM198006263022607","volume":"302","author":"ME King","year":"1980","unstructured":"King ME, Breslow JL, Lees RS (1980) Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med 302:1457\u20131459. https:\/\/doi.org\/10.1056\/NEJM198006263022607","journal-title":"N Engl J Med"},{"key":"5541_CR22","unstructured":"Winters JL (2010) Apheresis : principles and practice, 4th edn. Bethesda, Md., AABB Press"},{"key":"5541_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","volume":"208","author":"GR Thompson","year":"2010","unstructured":"Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M et al (2010) Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 208:317\u2013321. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.06.010","journal-title":"Atherosclerosis"},{"key":"5541_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1526-0968.2001.00328.x","volume":"5","author":"A Yamamoto","year":"2001","unstructured":"Yamamoto A, Harada-Shiba M, Kawaguchi A, Tsushima M (2001) Apheresis technology for prevention and regression of atherosclerosis. Ther Apher 5:221\u2013225. https:\/\/doi.org\/10.1046\/j.1526-0968.2001.00328.x","journal-title":"Ther Apher"},{"key":"5541_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1526-0968.2003.00073.x","volume":"7","author":"H Makino","year":"2003","unstructured":"Makino H, Harada-Shiba M (2003) Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial 7:397\u2013401. https:\/\/doi.org\/10.1046\/j.1526-0968.2003.00073.x","journal-title":"Ther Apher Dial"},{"key":"5541_CR26","doi-asserted-by":"publisher","first-page":"e101290","DOI":"10.1371\/journal.pone.0101290","volume":"9","author":"M Zanetti","year":"2014","unstructured":"Zanetti M, Zenti M, Barazzoni R, Zardi F, Semolic A, Messa MG et al (2014) HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. PLoS One 9:e101290. https:\/\/doi.org\/10.1371\/journal.pone.0101290","journal-title":"PLoS ONE"},{"key":"5541_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/01.ccx.0000244119.16377.75","volume":"12","author":"N Khuseyinova","year":"2006","unstructured":"Khuseyinova N, Koenig W (2006) Biomarkers of outcome from cardiovascular disease. Curr Opin Crit Care 12:412\u2013419. https:\/\/doi.org\/10.1097\/01.ccx.0000244119.16377.75","journal-title":"Curr Opin Crit Care"},{"key":"5541_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1567-5688(09)71812-4","volume":"10","author":"MJ Koziolek","year":"2009","unstructured":"Koziolek MJ, Mueller GA (2009) Impact of LDL-apheresis on inflammation and microcirculation. Atheroscler Suppl 10:56\u201358. https:\/\/doi.org\/10.1016\/S1567-5688(09)71812-4","journal-title":"Atheroscler Suppl"},{"key":"5541_CR29","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1744-9987.2006.00441.x","volume":"10","author":"KP Mellwig","year":"2006","unstructured":"Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W, Horstkotte D (2006) Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. Ther Apher Dial 10:510\u2013517. https:\/\/doi.org\/10.1111\/j.1744-9987.2006.00441.x","journal-title":"Ther Apher Dial"},{"key":"5541_CR30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1161\/01.cir.96.5.1381","volume":"96","author":"T Sampietro","year":"1997","unstructured":"Sampietro T, Tuoni M, Ferdeghini M, Ciardi A, Marraccini P, Prontera C et al (1997) Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 96:1381\u20131385. https:\/\/doi.org\/10.1161\/01.cir.96.5.1381","journal-title":"Circulation"},{"key":"5541_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00467-018-3906-6","volume":"33","author":"G Klaus","year":"2018","unstructured":"Klaus G, Taylan C, Buscher R, Schmitt CP, Pape L, Oh J et al (2018) Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity. Pediatr Nephrol 33:1199\u20131208. https:\/\/doi.org\/10.1007\/s00467-018-3906-6","journal-title":"Pediatr Nephrol"},{"key":"5541_CR32","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jacl.2016.08.006","volume":"10","author":"C Taylan","year":"2016","unstructured":"Taylan C, Schlune A, Meissner T, Azukaitis K, Udink Ten Cate FE, Weber LT (2016) Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia. J Clin Lipidol 10:1303\u20131310. https:\/\/doi.org\/10.1016\/j.jacl.2016.08.006","journal-title":"J Clin Lipidol"},{"key":"5541_CR33","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/CIRCULATIONAHA.106.671016","volume":"116","author":"J Rodenburg","year":"2007","unstructured":"Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E et al (2007) Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116:664\u2013668. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.671016","journal-title":"Circulation"},{"key":"5541_CR34","unstructured":"Chourdakis M, Buderus S, Dokoupil K, Oberhoffer R, Schwab KO, Wolf M, Zimmer KP, Koletzko B (2015) S2k-Leitlinien zur Diagnostik und Therapie von Hyperlipid\u00e4mien bei Kindern und Jugendlichen. http:\/\/www.aerztenetz-bad-berleburg.de\/images\/S2k-Leitlinie-Hyperlipidaemien-Kinder-Jugendliche.pdf Accessed."},{"key":"5541_CR35","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1161\/01.cir.0000058166.99182.54","volume":"107","author":"A Wiegman","year":"2003","unstructured":"Wiegman A, Rodenburg J, de Jongh S, Defesche JC, Bakker HD, Kastelein JJ et al (2003) Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 107:1473\u20131478. https:\/\/doi.org\/10.1161\/01.cir.0000058166.99182.54","journal-title":"Circulation"},{"key":"5541_CR36","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X et al (2016) Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 67:2578\u20132589. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.520","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"5541_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ et al (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract 23(Suppl 2):1\u201387. https:\/\/doi.org\/10.4158\/EP171764.APPGL","journal-title":"Endocr Pract"},{"key":"5541_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2011.06.016","volume":"218","author":"OS Descamps","year":"2011","unstructured":"Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC et al (2011) Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 218:272\u2013280. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.06.016","journal-title":"Atherosclerosis"},{"key":"5541_CR39","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA et al (2014) Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35:2146\u20132157. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274","journal-title":"Eur Heart J"},{"key":"5541_CR40","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:3478\u20133490a. https:\/\/doi.org\/10.1093\/eurheartj\/eht273","journal-title":"Eur Heart J"},{"key":"5541_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"5541_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/jca.21743","volume":"34","author":"D Garrity","year":"2019","unstructured":"Garrity D, Graves M, Linden J, St Pierre P, Ducharme P, Zhao Y et al (2019) Performance characteristics of the PowerFlow apheresis port: early experience. J Clin Apher 34:661\u2013665. https:\/\/doi.org\/10.1002\/jca.21743","journal-title":"J Clin Apher"},{"key":"5541_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13799","author":"M Golsorkhi","year":"2022","unstructured":"Golsorkhi M, Azarfar A, Abdipour A (2022) Vascular access in therapeutic apheresis: one size does not fit all. Ther Apher Dial. https:\/\/doi.org\/10.1111\/1744-9987.13799","journal-title":"Ther Apher Dial"},{"issue":"Suppl 1","key":"5541_CR44","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/trf.14479","volume":"58","author":"TS Ipe","year":"2018","unstructured":"Ipe TS, Marques MB (2018) Vascular access for therapeutic plasma exchange. Transfusion 58(Suppl 1):580\u2013589. https:\/\/doi.org\/10.1111\/trf.14479","journal-title":"Transfusion"},{"key":"5541_CR45","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1111\/trf.15512","volume":"59","author":"KL Gray","year":"2019","unstructured":"Gray KL, Steidley IG, Benson HL, Pearce CL, Bachman AM, Adamski J (2019) Implementation and 2-year outcomes of the first FDA-approved implantable apheresis vascular access device. Transfusion 59:3461\u20133467. https:\/\/doi.org\/10.1111\/trf.15512","journal-title":"Transfusion"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05541-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T14:08:09Z","timestamp":1671458889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05541-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5541"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05541-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The DEAL Funding Note was added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}